OS Therapies

Join us at the upcoming LD Micro event on October 29, where OS Therapies (NYSE: $OSTX) CEO Paul Romness and CBO Gerald Commissiong will present a corporate overview at 11:30 AM PT. Register to watch our presentation here: https://lnkd.in/g6qPWxzN https://lnkd.in/eTgPzsx9 #OSTherapies #LDMicro #InvestorConference 

At OS Therapies we value our current partners because we can’t do it alone. Thank you to all for your partnership. Children's Cancer Research Fund, The Osteosarcoma Institute, Canines-N-Kids Foundation, The Osteosarcoma Collaborative, Because of Daniel #osteosarcoma #noonefightsalone #together #partnerships #thankyou #cancerresearch #OSTX

The The Osteosarcoma Institute Institute has published the story of Lavinia the Mastiff and her battle with Osteosarcoma, the leading disease killer of dogs. OS Therapies has a canine version of its osteosarcoma cancer vaccine OST-HER2 that already has conditional approval. Upon completing a small study to get full approval, OS Therapies aims to launch the canine vaccine into the market in 2025. Our ability to find a way to treat bone cancer in animals provides a much higher success rate for treating it in humans which OS Therapies also seeks to address. https://lnkd.in/eY9ykuVY #osteosarcoma #canines #laviniathemastiff #dogs #cancervaccine #OSTX #cancerresearch

The The Osteosarcoma Institute Institute has published the story of Lavinia the Mastiff and her battle with Osteosarcoma, the leading disease killer of dogs. OS Therapies has a canine version of its osteosarcoma cancer vaccine OST-HER2 that already has conditional approval. Upon completing a small study to get full approval, OS Therapies aims to launch the canine vaccine into the market in 2025. Our ability to find a way to treat bone cancer in animals provides a much higher success rate for treating it in humans which OS Therapies also seeks to address. https://lnkd.in/eY9ykuVY #osteosarcoma #canines #laviniathemastiff #dogs #cancervaccine #OSTX #cancerresearch

We’re grateful for the journey we've been on as a public company and excited about the progress we’ve made in developing cancer treatments. From enrolling the last patient in our OST-HER2 Phase 2b osteosarcoma trial to joining Johnson & Johnson Innovation - JLABS, our commitment to innovation is stronger than ever. With positive preclinical data for ovarian cancer, the development of new tunable ADC candidates, and topline data from our OST-HER2 Phase 2b trial expected later this year, we remain focused on transforming care and improving lives. Thank you to our community for your continued support as we move forward with purpose and determination.  $OSTX #NYSE #osteosarcoma #OSTX #ourjourney #forwardprogress #cancerresearch

Our Tunable Antibody Drug Conjugates (tADCs) have the potential to revolutionize cancer treatment. Using SiLinkers™ technology, multiple therapeutic agents are delivered directly to tumors, maximizing effectiveness while minimizing damage to healthy cells. $OSTX #OSTX OS Therapies #antibodydrugconjugates  https://lnkd.in/evtA46gF

The global market for Antibody Drug Conjugates (ADCs) surpassed $10 billion last year, with projections estimating nearly $30 billion by 2028. OS Therapies is developing its tunable ADC (tADC) platform, which leverages proprietary silicone linker technology to deliver multiple tailored payloads, representing the next generation of targeted therapies. https://bit.ly/4e7enMG #OSTX #antibodydrugconjugates #siliconelinkertechnology #marketopportunity #cancerresearch

OS Therapies' $OSTX OST-HER2 (OST31-164) has received USDA provisional approval for treating Canine Osteosarcoma, with a completed pivotal efficacy study showing significant survival benefits. This progress de-risks the pathway for human Osteosarcoma treatments and lays the groundwork for the anticipated full market launch in 2025. https://bit.ly/3zmhm4S #OSTX #Osteosarcoma #cancer #petlovers #dogs

OS Therapies is harnessing a highly modified Listeria strain to target HER2-expressing cancer cells. Unlike the harmful strains in food contamination, there is zero possibility that the OS strain could recombine with wild Listeria or cause disease. Extensively tested before human use, this strain is designed to trigger a powerful immune response and is safely eliminated from the body. #cancerresearch #immuneresponse #investors #osteosarcoma #listeria https://bit.ly/3XsKZth

OS Therapies is excited to announce the development of two novel tunable Antibody Drug Conjugate (tADC)-based therapeutic candidates. The first targets breast, lung, and gastric cancers, while the second focuses on platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. With these additions, we are strengthening our pipeline and positioning the company as a key provider of intellectual property for innovative therapeutic product development. #CancerResearch #investors #OSTX https://bit.ly/4d419z8